Dr. Ziaeian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 UCLA Medical Plz
Ste 630
Los Angeles, CA 90024Phone+1 310-825-9011Fax+1 310-825-2092
Education & Training
- Ronald Reagan UCLA Medical CenterPost-Doctoral Fellowship, 2013 - 2016
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 2012 - 2016
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2008 - 2011
- University of California, Irvine, School of MedicineClass of 2008
Certifications & Licensure
- CA State Medical License 2011 - 2025
- CT State Medical License 2011 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- National Board of EchocardiographyDiplomate
Publications & Presentations
PubMed
- National Costs for Cardiovascular-Related Hospitalizations and Inpatient Procedures in the United States, 2016 to 2021.Amier Haidar, Aryan Gajjar, Rushi V Parikh, Peyman Benharash, Gregg C Fonarow
The American Journal of Cardiology. 2025-01-01 - Clinical Characteristics and Current Management of U.S. Adults at Elevated Risk for Heart Failure Using the PREVENT Equations: A Cross-Sectional Analysis.Jeremy B Sussman, Linnea M Wilson, James F Burke, Boback Ziaeian, Timothy S Anderson
Annals of Internal Medicine. 2024-12-17 - Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure.Amber B Tang, Boback Ziaeian, Javed Butler, Clyde W Yancy, Gregg C Fonarow
JAMA Cardiology. 2024-12-01
Journal Articles
- National Trends in Heart Failure Hospitalizations and Readmissions from 2010 to 2017Manyoo A Agarwal, Gregg C Fonarow, Boback Ziaeian, JAMA Cardiology
- Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy with Outcome for Patients with Heart FailureBoback Ziaeian, Clyde W Yancy, JAMA Cardiology
- Perceived Barriers to Sacubitril/Valsartan Use in Patients with Heart FailureKevin S Shah, Boback Ziaeian, Freny V Mody, Ali Nsair, Gregg C Fonarow, Journal of Cardiac Failure
- Join now to see all
Authored Content
- Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy with Outcome for Patients with Heart FailureMay 2020
- Perceived Barriers to Sacubitril/Valsartan Use in Patients with Heart FailureAugust 2018
Press Mentions
- More Americans Hospitalized, Readmitted for Heart FailureFebruary 16th, 2021
- Surgisphere Data Used in Two COVID Studies Called into QuestionJune 3rd, 2020
- Arterial Thrombosis in Patients with CancerApril 7th, 2020
- Join now to see all
Other Languages
- Spanish, Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: